

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
16 December 2021 (16.12.2021)



(10) International Publication Number
WO 2021/252780 A2

(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2021/036838

(22) International Filing Date:
10 June 2021 (10.06.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/037,985 11 June 2020 (11.06.2020) US

(71) Applicant: **TIZONA THERAPEUTICS** [US/US]; 4000
Shoreline Court, Suite 200, South San Francisco, California
94080 (US).

(72) Inventors: **BEERS, Courtney**; c/o Tizona Therapeutics,
4000 Shoreline Court, Suite 200, South San Francisco, Cal-
ifornia 94080 (US). **CHU, Ling Hon Matthew**; c/o Tizona
Therapeutics, 4000 Shoreline Court, Suite 200, South San
Francisco, California 94080 (US). **HODGES, Doug**; c/
o Tizona Therapeutics, 4000 Shoreline Court, Suite 200,
South San Francisco, California 94080 (US). **KOCHEL,
Christina M.**; c/o Tizona Therapeutics, 4000 Shoreline
Court, Suite 200, South San Francisco, California 94080
(US).

(74) Agent: **ANDERTON, H. Thomas**; K&L Gates LLP, 4
Embarcadero Center, Suite 1200, San Francisco, California
94111-5994 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))



(54) Title: BISPECIFIC IMMUNE CELL ENGAGERS WITH BINDING SPECIFICITY FOR HLA-G AND ANOTHER ANTIGEN

(57) Abstract: Provided herein are bispecific immune cell engagers with binding specificity for HLA-G and an additional antigen, including pharmaceutical compositions, diagnostic compositions, and kits.